Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades CinCor Pharma to Perform

Oppenheimer Downgrades CinCor Pharma to Perform

Oppenheimer analyst Jay Olson downgrades CinCor Pharma (NASDAQ:CINC) from Outperform to Perform.

November 29, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades CinCor Pharma (NASDAQ:CINC) from Outperform to Perform.

Tilray Ramps Up Pre-Roll Production As Competition Heats Up In Canada

August 30, 1:50 PM

Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) debuted its new 'Diamonds Collection' by its Premium cannabis lifestyle brand RIFF on Wednesday

November 16, 9:41 AM

Mizuho analyst Siti Panigrahi maintains LivePerson (NASDAQ:LPSN) with a Neutral and raises the price target from $57 to $69.

January 17, 3:25 PM

UBS analyst downgrades Ford to Neutral, amid concerns over Gen 2 EV lag and labor headwinds.

July 13, 7:32 AM

Baird analyst David Koning downgrades Verra Mobility (NASDAQ:VRRM) from Outperform to Neutral.